• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:54:46 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HOTH alert in real time by email
    SC 13G/A 1 ea135738-13ga1eitner_hoth.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1) 

     

    HOTH THERAPEUTICS, INC. 

    (Name of Issuer)

     

    COMMON STOCK 

    (Title of Class of Securities)

     

    44148G 10 5 

    (CUSIP Number)

     

    December 31, 2020 

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒Rule 13d-1(b)

     

    ☐Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

     

     

     

     

     

    CUSIP No. 44148G 10 5 

      

    1

    NAME OF REPORTING PERSONS

    S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     
    Matthew Eitner

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☐
    (b)
    ☐
    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States 

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

     
     18,750(1)

    6

    SHARED VOTING POWER

     

    0 

    7

    SOLE DISPOSITIVE POWER

     
    18,750(1)

    8

    SHARED DISPOSITIVE POWER

     
    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    18,750(1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     
    0.14% (based on 13,439,229 shares outstanding as of January 7, 2021)

    12

    TYPE OF REPORTING PERSON

     

    IN 

     

     

    (1)Represents (i) 15,000 shares of common stock held by Mr. Eitner and (ii) 3,750 shares of common stock underlying warrants to purchase common stock held by Mr. Eitner.

     

    2

     

      

    Item 1(a).Name of Issuer:

     

    Hoth Therapeutics, Inc., a Nevada corporation (“Issuer”).

     

    Item 1(b).Address of Issuer's Principal Executive Offices:

     

    1 Rockefeller Plaza, Suite 1039, New York, NY 10020.

     

    Item 2(a).Name of Person Filing.

     

    The statement is filed on behalf of Matthew Eitner (the “Reporting Person”).

     

    Item 2(b).Address of Principal Business Office or, if None, Residence.

     

    521 Fifth Avenue, 12th Floor, New York, NY 10175

     

    Item 2(c).Citizenship.

     

    The Reporting Person is a citizen of the United States.

     

    Item 2(d).Title of Class of Securities.

     

    Common Stock, par value $0.0001.

     

      Item 2(e). CUSIP Number.

     

    44148G 10 5

     

    Item 3.If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b), check whether the person filing is a

     

    (a) ☒ Broker or dealer registered under section 15 of the Act.

     

    Item 4.Ownership.

     

    (a) Amount beneficially owned: 18,750(1)

     

    (b) Percent of class 0.14% (based on 13, 439,229 shares common stock outstanding as of January 7, 2021)

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote: 18,750(1)

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 18,750(1)

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    (1)Represents (i) 15,000 shares of common stock held by Mr. Eitner and  (ii) 3,750 shares of common stock underlying warrants to purchase common stock held by Mr. Eitner.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5% of the class of securities, check following ☒.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    3

     

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    4

     

      

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Matthew Eitner
       
    Date: February 16, 2021 /s/ Matthew Eitner
      Matthew Eitner

     

     

    5

     

     

     

    Get the next $HOTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HOTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HOTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

      Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications NEW YORK, April 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ:HOTH), a clinical-stage biopharmaceutical company developing next-generation RNA-targeted precision therapies, today announced it has been granted a key patent by the Japan Patent Office (JPO), expanding its global intellectual property portfolio in RNA-based cancer therapeutics. The newly issued patent secures broad claims covering antisense oligome

      4/17/25 8:01:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

      Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 inOpen-Label Portion of CLEER HT-001 Phase 2a clinical Trial for Cancer EGFR Inhibitor-Induced Skin Toxicities Key Interim Results (Day 1–21): Patients experienced a 50% reduction in pruritus severity, with mean scores dropping from 1.6 on Day 1 to 0.8 by Day 21.Rapid symptom relief was observed, with mean scores improving to 1.0 by Day 7.Some patients achieved complete resolution of pruritus within the 21-day period.HT-001 was well tolerated, with no treatment-related serious adverse events reported.NEW YORK, April 15, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ:HOTH), a biopharmaceutical company focuse

      4/15/25 8:19:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

      NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently submitted NIH grant proposal focused on studying HT-ALZ—an FDA-approved NK-1 receptor antagonist—for its potential to reduce neuroinflammation and improve cognitive function in Alzheimer's disease (AD). The research collaboration is le

      4/2/25 8:02:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

      SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

      2/14/24 2:47:32 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Hoth Therapeutics Inc.

      SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)

      2/14/23 12:55:35 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

      SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

      2/8/23 6:07:04 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Knie Robb bought $16,750 worth of shares (25,000 units at $0.67), increasing direct ownership by 75% to 58,131 units (SEC Form 4)

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      8/19/24 8:00:03 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board

      NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir

      1/31/22 8:17:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $HOTH
    SEC Filings

    See more
    • SEC Form 4 filed by CEO and President Knie Robb

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      1/15/25 4:15:55 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Springer Graig

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      1/15/25 4:15:06 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sarnoff David

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      8/21/24 4:15:05 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoth Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

      5/2/25 8:20:24 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoth Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

      4/15/25 8:25:26 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Hoth Therapeutics Inc.

      10-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

      3/28/25 4:15:47 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care